Cargando…

Potential use of custirsen to treat prostate cancer

Over the last few years, five agents have demonstrated a survival benefit over a comparator treatment or placebo in the treatment of metastatic castration-resistant prostate cancer and have been approved by the US Food and Drug Administration: sipuleucel-T (a dendritic cell immunotherapy); cabazitax...

Descripción completa

Detalles Bibliográficos
Autor principal:	Higano, Celestia S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699352/ https://www.ncbi.nlm.nih.gov/pubmed/23836992 http://dx.doi.org/10.2147/OTT.S33077

Ejemplares similares

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
por: Blumenstein, Brent, et al.
Publicado: (2013)

Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
por: Zhang, Xuebao, et al.
Publicado: (2019)

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Assessing the nutritional needs of men with prostate cancer
por: McLaughlin, Kaitlin, et al.
Publicado: (2019)

Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach
por: Bossio, Jennifer A., et al.
Publicado: (2021)

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
por: Graff, Julie N, et al.
Publicado: (2015)

Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors
por: Cherrier, Monique M., et al.
Publicado: (2021)

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
por: Gross, Mitchell, et al.
Publicado: (2007)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic
por: Flannigan, Ryan, et al.
Publicado: (2020)

Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial
por: Finelli, Antonio, et al.
Publicado: (2021)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Clinic Utilization and Characteristics of Patients Accessing a Prostate Cancer Supportive Care Program’s Sexual Rehabilitation Clinic
por: Wong, Julie, et al.
Publicado: (2020)

Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study
por: Cherrier, Monique M, et al.
Publicado: (2010)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
por: Small, E J, et al.
Publicado: (2014)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
por: Nguyen, Holly M., et al.
Publicado: (2017)

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
por: George, Daniel J., et al.
Publicado: (2022)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer
por: Hawlina, Simon, et al.
Publicado: (2023)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2023)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
por: Jacobson, Dionna, et al.
Publicado: (2022)

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
por: Cherrier, M. M., et al.
Publicado: (2018)

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
por: Smith, Matthew R., et al.
Publicado: (2016)

Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review
por: Nelson, Adam J., et al.
Publicado: (2023)

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
por: Morris, Michael J., et al.
Publicado: (2019)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Emerging Immunotherapy Approaches for Treating Prostate Cancer
por: Meng, Lingbin, et al.
Publicado: (2023)

Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes
por: Gordon, Ryan R., et al.
Publicado: (2014)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
por: Leung, David Ka-Wai, et al.
Publicado: (2021)

Aggressive Prostate Cancer in Patients Treated with Active Surveillance
por: Tohi, Yoichiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_redr3332r2ikgus82rmevhg9i3